Higher-quality evidence on the therapeutic efficacy of BRAF inhibitors in GBM has been documented by the VE-BASKET trial (59), a basket trial of BRAF V600E mutation-positive solid tumors, evaluating the safety and effectiveness of vemurafenib 960 mg twice per day continuously after tumor progression with standard therapy. The gene discussed is BRAF; the disease is glioblastoma.